Conformational Alterations of the Cell Surface of Monomeric and Dimeric β2m-Free HLA-I (Proto-HLA) May Enable Novel Immune Functions in Health and Disease
Open Access
- 4 July 2024
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (7) , 6961-6985
Abstract
Human leukocyte antigens (HLAs) are polymorphic glycoproteins expressed on the cell surface of nucleated cells and consist of two classes, HLA class I and HLA class II. In contrast, in mice, these molecules, known as H-2, are expressed on both nucleated cells and erythrocytes. HLA-I molecules (Face-1) are heterodimers consisting of a polypeptide heavy chain (HC) and a light chain, B2-microglobulin (B2m). The heterodimers bind to antigenic peptides and present them to the T-cell receptors of CD8+ cytotoxic T lymphocytes. The HCs can also independently emerge on the cell surface as B2m-free HC monomers without peptides (Face-2). Early investigators suggested that the occurrence of B2m-free HCs on the cell surface resulted from the dissociation of B2m from Face-1. However, others documented the independent emergence of B2m-free HCs (Face-2) from the endoplasmic reticulum (ER) to the cell surface. The clustering of such HC molecules on either the cell surface or on exosomes resulted in the dimerization of B2m-free HCs to form homodimers (if the same allele, designated as Face-3) or heterodimers (if different alleles, designated as Face-4). Face-2 occurs at low levels on the cell surface of several normal cells but is upregulated on immune cells upon activation by proinflammatory cytokines and other agents such as anti-CD3 antibodies, phytohemagglutinin, and phorbol myristate acetate. Their density on the cell surface remains high as long as the cells remain activated. After activation-induced upregulation, Face-2 molecules undergo homo- and heterodimerization (Face-3 and Face-4). Observations made on the structural patterns of HCs and their dimerization in sharks, fishes, and tetrapod species suggest that the formation of B2m-free HC monomers and dimers is a recapitalization of a phylogenetically conserved event, befitting the term Proto-HLA for the B2m-free HCs. Spontaneous arthritis occurs in HLA-B27+ mice lacking B2m (HLA-B27+ B2m−/−) but not in HLA-B27+ B2m+/+ mice. Anti-HC-specific monoclonal antibodies (mAbs) delay disease development. Some HLA-I polyreactive mAbs (MEM series) used for immunostaining confirm the existence of B2m-free variants in several cancer cells. The conformational alterations that occur in the B2m-free HCs enable them to interact with several inhibitory and activating receptors of cellular components of the innate (natural killer (NK) cells) and adaptive (T and B cells) immune systems. The NK cells express killer immunoglobulin-like receptors (KIRs), whereas leukocytes (T and B lymphocytes, monocytes/macrophages, and dendritic cells) express leukocyte immunoglobulin-like receptors (LILRs). The KIRs and LILRs include activating and inhibitory members within their respective groups. This review focuses on the interaction of KIRs and LILRs with B2m-free HC monomers and dimers in patients with spondylarthritis. Several investigations reveal that the conformational alterations occurring in the alpha-1 and alpha-2 domains of B2m-free HCs may facilitate immunomodulation by their interaction with KIR and LILR receptors. This opens new avenues to immunotherapy of autoimmune diseases and even human cancers that express B2m-free HCs.Keywords
Funding Information
- Mark Terasaki, the first son of the late Paul Ichiro Terasaki of the Terasaki Foundation Laboratory (TFL)
This publication has 167 references indexed in Scilit:
- HLA‐E allelic genotype correlates with HLA‐E plasma levels and predicts early progression in chronic lymphocytic leukemiaCancer, 2016
- Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapyInternational Journal of Cancer, 2014
- Gastric cancer progression may involve a shift in HLA‐E profile from an intact heterodimer to β2‐microglobulin‐free monomerInternational Journal of Cancer, 2013
- Inhibiting HLA–B27 homodimer–driven immune cell inflammation in spondylarthritisArthritis & Rheumatism, 2012
- Interaction of HLA‐B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA‐B27 heterotrimers, is independent of the sequence of bound peptideEuropean Journal of Immunology, 2007
- Lymphoblastoid cells express HLA‐B27 homodimers both intracellularly and at the cell surface following endosomal recyclingEuropean Journal of Immunology, 2003
- Cell‐surface expression and immune receptor recognition of HLA–B27 homodimersArthritis & Rheumatism, 2002
- β2 -Microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chainsEuropean Journal of Immunology, 1998
- Exogenous peptide ligand influences the expression and half‐life of free HLA class I heavy chains ubiquitously detected at the cell surfaceEuropean Journal of Immunology, 1994
- A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon‐treated human melanoma cellsEuropean Journal of Immunology, 1985